The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
The pharmacology of second-generation chimeric antigen receptors
Open accessAbstract
Second-generation chimeric antigen receptors (CARs) retarget and reprogramme T cells to augment their antitumour efficacy. The combined activating and co-stimulatory domains incorporated in these CARs critically determine the function, differentiation, metabolism and persistence of engineered T cells. CD19-targeted CARs that incorporate CD28 or 4-1BB signalling domains are the best known to date. Both have shown remarkable complete remission rates in patients with refractory B cell malignancies. Recent data indicate that CD28-based CARs direct a brisk proliferative response and boost effector functions, whereas 4-1BB-based CARs induce a more progressive T cell accumulation that may compensate for less immediate potency. These distinct kinetic features can be exploited to further develop CAR-based T cell therapies for a variety of cancers. A new field of immunopharmacology is emerging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–240 of 240
The Survival of Antigen-Stimulated T Cells Requires NFκB-Mediated Inhibition of p73 Expression
Wan, Y. Y., & DeGregori, J. V. (2003) · Immunity · doi:10.1016/s1074-7613(03)00053-0 · Cited by 89
Fann, M., Chiu, W. K., Wood, W. H., Levine, B. L., Becker, K. G., & Weng, N. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00262.x · Cited by 84
New simplified molecular design for functional T cell receptor
Brocker, T., Peter, A., Traunecker, A., & Karjalainen, K. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230705 · Cited by 84
TNF family ligands define niches for T cell memory
Sabbagh, L., Snell, L. M., & Watts, T. H. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.06.001 · Cited by 83
CD137 Promotes Proliferation and Survival of Human B Cells
Zhang, X., Voskens, C., Sallin, M. A., Maniar, A., Montes, C. L., Zhang, Y., Lin, W., Li, G., Burch, E. E., Tan, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901619 · Cited by 81
Monoclonal antibody 9.3 and anti‐CD11 antibodies define reciprocal subsets of lymphocytes
Yamada, H., Martin, P. J., Bean, M. A., Braun, M. P., Beatty, P. G., Sadamoto, K., & Hansen, J. A. (1985) · European Journal of Immunology · doi:10.1002/eji.1830151204 · Cited by 77
OX40 Drives Protective Vaccinia Virus-Specific CD8 T Cells,
Salek‐Ardakani, S., Moutaftsi, M., Crotty, S., Sette, A., & Croft, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.7969 · Cited by 76
Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells
Chu, N., Debenedette, M. A., Stiernholm, B. J., Barber, B. H., & Watts, T. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.7.3081 · Cited by 75
Wang, C., McPherson, A. J., Jones, R. B., Kawamura, K. S., Lin, G. H. Y., Lang, P. A., Ambagala, T., Pellegrini, M., Calzascia, T., Aidarus, N., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110675 · Cited by 73
Faris, M., Kokot, N., Lee, L., & Nel, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27366 · Cited by 72
Costimulation of human CD28– T cells by 4‐1BB ligand
Bukczynski, J., Wen, T., & Watts, T. H. (2003) · European Journal of Immunology · doi:10.1002/immu.200310020 · Cited by 72
T Cells Expressing Constitutively Active Akt Resist Multiple Tumor-associated Inhibitory Mechanisms
Sun, J., Dotti, G., Huye, L. E., Foster, A. E., Savoldo, B., Gramatges, M. M., Spencer, D. M., & Rooney, C. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.185 · Cited by 69
Carr, J. M., Carrasco, M. J., Thaventhiran, J. E. D., Bambrough, P. J., Kraman, M., Edwards, A. D., Al‐Shamkhani, A., & Fearon, D. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609706104 · Cited by 65
CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells
Johnson‐Léger, C. (1998) · International Immunology · doi:10.1093/intimm/10.8.1083 · Cited by 63
Lee, H., Nam, K., Park, S., & Kwon, B. S. (2003) · European Journal of Immunology · doi:10.1002/eji.200323996 · Cited by 61
Dual immunoregulatory pathways of 4-1BB signaling
Vinay, D. S., Cha, K., & Kwon, B. S. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0072-2 · Cited by 60
Biphasic role of 4‐1BB in the regulation of mouse cytomegalovirus‐specific CD8+ T cells
Humphreys, I. R., Lee, S., Jones, M., Loewendorf, A. I., Emma Gostick, D., Price, D. A., Benedict, C. A., Ware, C. F., & Croft, M. (2010) · European Journal of Immunology · doi:10.1002/eji.200940256 · Cited by 60
Regulation of Thymic NKT Cell Development by the B7-CD28 Costimulatory Pathway
Williams, J. A., Lumsden, J. M., Xiang, Y., Feigenbaum, L., Zhang, J., Steinberg, S. M., & Hodes, R. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.907 · Cited by 59
NF‐κB and AP‐1 regulate activation‐dependent CD137 (4‐1BB) expression in T cells
Kim, J., Kim, H. W., Baek, K., & Kang, C. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00326-0 · Cited by 58
TNF受容体(TNFR)関連因子(TRAF)3はTRAF結合性TNFRによる非定型的NFκB経路のTRAF2/5介在性活性化の阻害物質として働く
Hauer, J., Püschner, S., Ramakrishnan, P., Simon, U., Bongers, M., Federle, C., & Engelmann, H. (2005) · Cited by 58
Qualitative and Quantitative Effects of CD28/B7-Mediated Costimulation on Naive T Cells In Vitro
Manickasingham, S. P., Anderton, S. M., Burkhart, C., & Wraith, D. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.3827 · Cited by 56
Smeets, R. L., Fleuren, W., He, X., Vink, P. M., Wijnands, F., Gorecka, M., Klop, H., Bauerschmidt, S., Garritsen, A., Koenen, H. J. P. M., et al. (2012) · BMC Immunology · doi:10.1186/1471-2172-13-12 · Cited by 55
Habibagahi, M., Phan, T. T., & Searle, P. F. (2007) · International Immunology · doi:10.1093/intimm/dxm106 · Cited by 55
Zhang, T., & Sentman, C. L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201314 · Cited by 50
Cheadle, E. J., Sheard, V., Rothwell, D. G., Bridgeman, J. S., Ashton, G., Hanson, V., Mansoor, A. W., Hawkins, R. E., & Gilham, D. E. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302148 · Cited by 48
Gargett, T., Fraser, C. K., Dotti, G., Yvon, E. S., & Brown, M. P. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000061 · Cited by 46
Lewis, D. E., Merched-Sauvage, M., Goronzy, J. J., Weyand, C. M., & Vallejo, A. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402194200 · Cited by 45
Dossett, M. L., Teague, R. M., Schmitt, T. M., Tan, X., Cooper, L. J. N., Pinzon, C., & Greenberg, P. D. (2009) · Molecular Therapy · doi:10.1038/mt.2008.300 · Cited by 42
Barber, A. E., & Sentman, C. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900721 · Cited by 39
Venuprasad, K., Parab, P. B., Prasad, D. V. R., Sharma, S., Banerjee, P. P., Deshpande, M. S., Mitra, D. K., Pal, S., Bhadra, R., Mitra, D., et al. (2001) · European Journal of Immunology · Cited by 38
Enhanced antitumor activity mediated by human 4‐1BB‐engineered T cells
Daniel‐Meshulam, I., Horovitz‐Fried, M., & Cohen, C. J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28320 · Cited by 34
Differential Down-Regulation Of CD28 By B7-1 And B7-2 Engagement1
Eck, S., Chang, D., Wells, A. D., & Turka, L. A. (1997) · Transplantation · doi:10.1097/00007890-199711270-00025 · Cited by 34
Lee, S. J., Kim, Y. H., Hwang, S. H., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242842 · Cited by 31
Regulation of CD28 expression on CD8+ T cells by CTLA-4
Berg, M., & Zavazava, N. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0107065 · Cited by 31
Dendritic Cells and Stat3 Are Essential for CD137-Induced CD8 T Cell Activation-Induced Cell Death
Zhang, B., Zhang, Y., Niu, L., Vella, A. T., & Mittler, R. S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902713 · Cited by 28
The murine homologue of the T lymphocyte antigen CD28.
Gross, J. A., John, T., & Allison, J. P. (1990) · Cited by 27
4-1BBL costimulation retrieves CD28 expression in activated T cells
Habibagahi, M., Jaberipour, M., & Searle, P. F. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.01.003 · Cited by 24
Changes in lymphocytes′ telomerase activity by 4-1BB costimulation
Habibagahi, M., Ahmad, H., Jaberipour, M., & Fereshteh, M. (2014) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.137906 · Cited by 3
Activation of the Ras-related GTPase Rap1 by thymocyte TCR engagement and during selection
(2000) · Pure Amsterdam UMC · doi:10.1002/1521-4141(200010)30:10 · Cited by 3
(1999) · doi:10.1002/(sici)1521-4141(199903)29:03<789::aid-immu789>3.0.co;2-5
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Self-citationNF-κB in biology and targeted therapy: new insights and translational implications
Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01757-9 · Cited by 2,047
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Metadata
- Authors
- van der Stegen, S. J. C., Hamieh, M., & Sadelain, M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-07
- Volume
- 14
- Issue
- 7
- Pages
- 499-509
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1604141497
- Cited by
- 555
- References
- 240
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.